Debra Mclaughlin

NPI: 1568955342
Total Payments
$4,138
2022 Payments
$1,360
Companies
1
Transactions
14

Payment Breakdown by Category

Consulting$4,138 (100.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $4,138 14 100.0%

Top Paying Companies

Company Total Records Latest Year
Novartis Pharmaceuticals Corporation $4,138 14 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2022 $1,360 2 Novartis Pharmaceuticals Corporation ($1,360)
2021 $2,778 12 NOVARTIS PHARMACEUTICALS CORPORATION ($2,778)

All Payment Transactions

14 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
08/14/2022 Novartis Pharmaceuticals Corporation GILENYA (Drug) Consulting Fee Cash or cash equivalent $930.00 General
Category: NEUROSCIENCE
08/13/2022 Novartis Pharmaceuticals Corporation GILENYA (Drug) Consulting Fee Cash or cash equivalent $430.00 General
Category: NEUROSCIENCE
09/23/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
09/09/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
07/08/2021 NOVARTIS PHARMACEUTICALS CORPORATION GILENYA (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
07/08/2021 NOVARTIS PHARMACEUTICALS CORPORATION GILENYA (Drug) Consulting Fee Cash or cash equivalent $24.64 General
Category: NEUROSCIENCE
06/17/2021 NOVARTIS PHARMACEUTICALS CORPORATION GILENYA (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
06/17/2021 NOVARTIS PHARMACEUTICALS CORPORATION GILENYA (Drug) Consulting Fee Cash or cash equivalent $4.48 General
Category: NEUROSCIENCE
06/03/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
06/03/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $32.48 General
Category: NEUROSCIENCE
04/22/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
04/22/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $30.80 General
Category: NEUROSCIENCE
04/01/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $380.00 General
Category: NEUROSCIENCE
04/01/2021 NOVARTIS PHARMACEUTICALS CORPORATION MAYZENT (Drug) Consulting Fee Cash or cash equivalent $25.76 General
Category: NEUROSCIENCE

About Debra Mclaughlin

Debra Mclaughlin is a Family healthcare provider based in Kingston, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2018. The National Provider Identifier (NPI) number assigned to this provider is 1568955342.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Debra Mclaughlin has received a total of $4,138 in payments from pharmaceutical and medical device companies, with $1,360 received in 2022. These payments were reported across 14 transactions from 1 company. The most common payment nature is "Consulting Fee" ($4,138).

Practice Information

  • Specialty Family
  • Other Specialties Family, Family
  • Location Kingston, NH
  • Active Since 06/07/2018
  • Last Updated 06/16/2018
  • Taxonomy Code 363LF0000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1568955342

Products in Payments

  • GILENYA (Drug) $2,149
  • MAYZENT (Drug) $1,989

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Family Doctors in Kingston